Literature DB >> 33219489

The montreal cognitive assessment and mini-mental state examination visuoexecutive subtests in acute ischemic stroke patients and their correlations with demographic and clinical factors.

Wei Wang1,2, Fang-Ming Dong1,2, Kai Shao1,2, Shang-Zun Guo3,2, Zhong-Min Zhao1,2, Yi-Ming Yang3,2, Ya-Xue Song2, Jian-Hua Wang4.   

Abstract

Visuoexecutive impairment is common among acute ischemic stroke patients. This study aimed to examine the ability of the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) visuoexecutive subtests to detect visuoexecutive abnormality in acute ischemic stroke patients and to identify the predictors for their impairments. 336 patients who completed the MMSE and MoCA were enrolled in this study. We compared the proportion of participants with incorrect MoCA visuoexecutive tasks and MMSE pentagon copying. Multivariate logistic regression analysis was used to evaluate the associations between the visuoexecutive dysfunction and demographic and clinical characteristics in the samples. Among all the participants, the MoCA detected more visuoexecutive dysfunction than the MMSE (88.69% vs. 45.83%, respectively; p < 0.001). The predictors identified by the univariate analysis included the factors of gender, age, educational level, smoking, alcohol consumption, Oxfordshire Community Stroke Project (OCSP), previous strokes, initial NIHSS score and number of old lacunar infarctions, while from the multivariate logistic regression analysis, the factors of age, educational level, NIHSS score, previous strokes and number of old lacunar infarctions served as predictive factors for the visuoexecutive impairment in acute stroke patients. In conclusion, visuoexecutive impairment is associated with the factors of the educational level, stroke severity, stroke history and number of old lacunar infarctions. Our findings may guide the clinicians to intervene the risks for the patients at an early stage after stroke and form the basis for good rehabilitation plans.
© 2020. Belgian Neurological Society.

Entities:  

Keywords:  Acute ischemic stroke; Cognitive impairment; MMSE; MoCA; Visuoexecutive function

Mesh:

Year:  2020        PMID: 33219489     DOI: 10.1007/s13760-020-01479-z

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  33 in total

1.  Neuropsychological screening in the acute phase of cerebrovascular diseases.

Authors:  Ilaria Cova; Francesco Mele; Federica Zerini; Laura Maggiore; Valentina Cucumo; Michela Brambilla; Silvia Rosa; Pierluigi Bertora; Emilia Salvadori; Simone Pomati; Leonardo Pantoni
Journal:  Acta Neurol Scand       Date:  2020-08-05       Impact factor: 3.209

2.  Educational history is an independent predictor of cognitive deficits and long-term survival in postacute patients with mild to moderate ischemic stroke.

Authors:  Johanna Ojala-Oksala; Hanna Jokinen; Valtteri Kopsi; Kalevi Lehtonen; Liisa Luukkonen; Antti Paukkunen; Lotte Seeck; Susanna Melkas; Tarja Pohjasvaara; Pekka Karhunen; Marja Hietanen; Timo Erkinjuntti; Niku Oksala
Journal:  Stroke       Date:  2012-08-30       Impact factor: 7.914

3.  A comparison between the MoCA and the MMSE visuoexecutive sub-tests in detecting abnormalities in TIA/stroke patients.

Authors:  Lauren M Mai; Luciano A Sposato; Peter M Rothwell; Vladimir Hachinski; Sarah T Pendlebury
Journal:  Int J Stroke       Date:  2016-02-10       Impact factor: 5.266

4.  Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.

Authors:  Hyuk Sung Kwon; Dongwhane Lee; Min Hwan Lee; Sungwook Yu; Jae-Sung Lim; Kyung-Ho Yu; Mi Sun Oh; Ji-Sung Lee; Keun-Sik Hong; Eun-Jae Lee; Dong-Wha Kang; Sun U Kwon
Journal:  J Neurol       Date:  2019-11-12       Impact factor: 4.849

5.  The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome.

Authors:  Joan Toglia; Kerri A Fitzgerald; Michael W O'Dell; Andrea R Mastrogiovanni; C David Lin
Journal:  Arch Phys Med Rehabil       Date:  2011-05       Impact factor: 3.966

6.  Early Cognitive Assessment Following Acute Stroke: Feasibility and Comparison between Mini-Mental State Examination and Montreal Cognitive Assessment.

Authors:  Satoshi Suda; Kanako Muraga; Akiko Ishiwata; Takuya Nishimura; Junya Aoki; Takuya Kanamaru; Kentaro Suzuki; Yuki Sakamoto; Takehiro Katano; Koichiro Nagai; Seira Hatake; Sera Satoi; Noriko Matsumoto; Chikako Nito; Yasuhiro Nishiyama; Masahiro Mishina; Kazumi Kimura
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-02-14       Impact factor: 2.136

7.  Clinical Predictors of Engagement in Inpatient Rehabilitation Among Stroke Survivors With Cognitive Deficits: An Exploratory Study.

Authors:  Emily A Kringle; Lauren Terhorst; Meryl A Butters; Elizabeth R Skidmore
Journal:  J Int Neuropsychol Soc       Date:  2018-03-19       Impact factor: 2.892

8.  Cognitive screening in the acute stroke setting.

Authors:  Daniel J Blackburn; Leila Bafadhel; Marc Randall; Kirsty A Harkness
Journal:  Age Ageing       Date:  2012-08-24       Impact factor: 10.668

9.  Comparison of the Mini-Mental State Examination and Montreal Cognitive Assessment executive subtests in detecting post-stroke cognitive impairment.

Authors:  Chen Fu; Xianglan Jin; Baoxin Chen; Feiran Xue; Huanmin Niu; Rongjuan Guo; Zhigang Chen; Hong Zheng; Le Wang; Yunling Zhang
Journal:  Geriatr Gerontol Int       Date:  2017-07-04       Impact factor: 2.730

10.  Screening for Mild Cognitive Impairment in Parkinson's Disease: Comparison of the Italian Versions of Three Neuropsychological Tests.

Authors:  Angela Federico; Alice Maier; Greta Vianello; Daniela Mapelli; Michela Trentin; Giampietro Zanette; Alessandro Picelli; Marialuisa Gandolfi; Stefano Tamburin
Journal:  Parkinsons Dis       Date:  2015-11-08
View more
  1 in total

1.  Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

Authors:  Vasileios K Kavouridis; Keith L Ligon; Patrick Y Wen; J Bryan Iorgulescu
Journal:  J Neurooncol       Date:  2022-04-26       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.